BiotechTube

BEAM-201

Phase 1/2Active
0 watching 0 views this week💤 Quiet
36
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Lymphoblastic Lymphoma

Conditions

Lymphoblastic Lymphoma, T-Cell Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Leukemia

Trial Timeline

May 25, 2023 → Dec 1, 2026

NCT ID
NCT05885464

About BEAM-201

BEAM-201 is a phase 1/2 stage product being developed by Beam Therapeutics for Lymphoblastic Lymphoma. The current trial status is active. This product is registered under clinical trial identifier NCT05885464. Target conditions include Lymphoblastic Lymphoma, T-Cell Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Leukemia.

Hype Score Breakdown

Clinical
13
Activity
8
Company
5
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT05885464Phase 1/2Active

Competing Products

20 competing products in Lymphoblastic Lymphoma

See all competitors
ProductCompanyStageHype Score
Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T CellsCSPC Pharmaceutical Group LimitedPhase 2
51
VCL-CB01Astellas PharmaPhase 2
52
SHP674Kyowa KirinPhase 2
52
LY3039478 + Dexamethasone + PlaceboEli LillyPhase 1/2
41
Venetoclax + Navitoclax + Dexamethasone + Vincristine + Calaspargase Pegol + Dasatinib + Cytarabine + Blinatumomab + Methotrexate + Mercaptopurine + Cyclophosphamide + Etoposide + Leucovorin + Intrathecal Triples + Pegaspargase + Erwinia asparaginaseAbbViePhase 1/2
41
ABT-348 + ABT-348 + ABT-348 and azacitidine + ABT-348AbbViePhase 1
33
Dexamethasone + Vincristine + Daunorubicin + Calaspargase pegol + Dasatinib + Venetoclax + Bortezomib + Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine) + Cyclophosphamide + Cytarabine + Mercaptopurine + Nelarabine + Methotrexate + ThioguanineAbbViePhase 2
52
Navitoclax + Chemotherapy + VenetoclaxAbbViePhase 1
33
Venetoclax + Dexamethasone + Inotuzumab OzogamicinAbbViePhase 1
33
Dasatinib + Methotrexate + Prednisone + Rituximab + Venetoclax + BlinatumomabAbbViePhase 1
33
Capivasertib + Venetoclax + Intrathecal chemotherapyAbbViePhase 1/2
41
Selumetinib + DexamethasoneAstraZenecaPhase 1/2
41
AZD3632 + PosaconazoleAstraZenecaPhase 1/2
41
AZD0486AstraZenecaPhase 1/2
41
blinatumomab + pembrolizumabMerckPhase 1/2
41
Zilovertamab vedotinMerckPhase 1/2
41
MK0752, (Notch Inhibitor)MerckPhase 1
33
Standard chemotherapy + ImatinibNovartisPhase 2
52
CTL019NovartisPhase 3
77
Ribociclib + Dexamethasone + EverolimusNovartisPhase 1
33

Other Products from Beam Therapeutics

BEAM-101Phase 1/2
36
BEAM-301: Single dose of BEAM-301 administered by IVPhase 1/2
36
BEAM-302Phase 1/2
36
BEAM-103 + Placebo ComparatorPhase 1
28
Allogeneic anti-CD7 CAR-T cells (BEAM-201)Phase 1
28